Structure via PubChem · Public domain (PubChem)
bupropion/naltrexone
Sign in to saveAlso known as bupropion hydrochloride / naltrexone hydrochloride, bupropion / naltrexone, Contrave
Naltrexone/bupropion, sold under the brand name Contrave among others, is a fixed-dose combination medication for the management of chronic obesity in adults in combination with a reduced-calorie diet and increased physical activity. It contains naltrexone, an opioid antagonist, and bupropion, an aminoketone atypical antidepressant. It is taken by mouth. Both medications have individually shown some evidence of effectiveness in weight loss, and the combination has been shown to have some synergistic effects on weight.
Chemical data
- Formula
- C33H41ClN2O5
- Molecular weight
- 581.1 g/mol
- IUPAC name
- (4R,4aS,7aR,12bS)-3-(cyclopropylmethyl)-4a,9-dihydroxy-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-one;2-(tert-butylamino)-1-(3-chlorophenyl)propan-1-one
- SMILES
- CC(C(=O)C1=CC(=CC=C1)Cl)NC(C)(C)C.C1CC1CN2CC[C@]34[C@@H]5C(=O)CC[C@]3([C@H]2CC6=C4C(=C(C=C6)O)O5)O
- InChIKey
- KVNBDVQGENTICK-ITLPAZOVSA-N
- Polar surface area
- 99.1 Ų
- H-bond donors
- 3
- H-bond acceptors
- 7
- Formal charge
- 0
via PubChem
Wikidata facts
- Instance of
- mixture
- Has part
- naltrexone
Show 2 more facts
- legal status (medicine)
- boxed warning
- isomeric SMILES
- CC(NC(C)(C)C)C(=O)c1cccc(Cl)c1.O=C1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
via Wikidata · CC0
~6 min read
Encyclopedic overview
9 sectionsContents
- Medical uses
- Available forms
- Contraindications
- Adverse effects
- Mechanism of action
- History
- Society and culture
- Economics
- References
Naltrexone/bupropion, sold under the brand name Contrave among others, is a fixed-dose combination medication for the management of chronic obesity in adults in combination with a reduced-calorie diet and increased physical activity. It contains naltrexone, an opioid antagonist, and bupropion, an aminoketone atypical antidepressant. It is taken by mouth. Both medications have individually shown some evidence of effectiveness in weight loss, and the combination has been shown to have some synergistic effects on weight.
In September 2014, a sustained release formulation of the drug was approved for marketing in the United States under the brand name Contrave. The combination was subsequently approved in the European Union in the spring of 2015, where it is sold under the name Mysimba. It was approved in Canada under the Contrave brand name in 2018.
Excerpted from Wikipedia’s “bupropion/naltrexone” article, available under the CC BY-SA 4.0 licence.